Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Nova Eye Medical ( (AU:EYE) ) has issued an announcement.
Nova Eye Medical has reported positive 12‑month clinical outcomes from its iTrack Global Data Registry, an independently managed, prospective real-world database now comprising more than 600 eyes contributed by 20 surgeons across 20 international sites. The latest annual statistical report shows 409 eyes with one-year follow-up, demonstrating an 85% success rate in reducing intraocular pressure in patients with baseline pressure above 18 mmHg and an average 40% reduction in medication use, alongside only six minor, self-resolving adverse events. These results compare favourably with other minimally invasive glaucoma surgery options and are expected to strengthen the clinical and safety case for canaloplasty with iTrack, supporting broader surgical adoption, payer engagement, market access, and future peer-reviewed publications that could further entrench Nova Eye’s position in the glaucoma treatment market.
The most recent analyst rating on (AU:EYE) stock is a Hold with a A$0.19 price target. To see the full list of analyst forecasts on Nova Eye Medical stock, see the AU:EYE Stock Forecast page.
More about Nova Eye Medical
Nova Eye Medical Limited is a medical technology company focused on ophthalmic treatment devices for glaucoma, developing, manufacturing and selling proprietary technologies used by eye surgeons worldwide. Its portfolio includes the iTrack Advance minimally invasive glaucoma surgery (MIGS) consumable, designed to restore the eye’s natural outflow pathway and reduce reliance on anti-glaucoma medications in mild to moderate glaucoma, and the Molteno3 glaucoma drainage device platform for severe glaucoma, which aims to improve long-term intraocular pressure control and streamline surgical procedures. The company operates sales headquarters in Fremont, California, supported by a global distributor network, with manufacturing facilities in the United States and New Zealand.
Average Trading Volume: 367,347
Technical Sentiment Signal: Buy
Current Market Cap: A$54.12M
For an in-depth examination of EYE stock, go to TipRanks’ Overview page.